XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets-Additional Information
 6 Months Ended
Dec. 31, 2018
Balance Sheets Additional Information [Abstract]  
Balance Sheets-Additional Information
4.     Balance Sheets—Additional Information
 
As of
    
December 31,
2018
    
June 30,
2018
  
Inventories                          
Raw materials
       $ 80,649         $ 62,373    
Work-in-process
         14,907           14,731    
Finished goods
         97,543           101,066    
        $ 193,099         $ 178,170    
 
We evaluate our investments in equity method investees for impairment if circumstances indicate that the fair value of the investment may be impaired. The assets underlying a $3,141 equity investment are currently idled; we have concluded the investment is not currently impaired, based on expected future operating cash flows and/or disposal value.
As of
    
December 31,
2018
    
June 30,
2018
  
Accrued expenses and other current liabilities                          
Employee related
       $ 21,282         $ 27,333    
Commissions and rebates
         7,510           7,341    
Insurance-related
         1,563           1,168    
Professional fees
         4,599           4,350    
Income and other taxes
         4,122           3,610    
Acquisition-related consideration
         3,928           12,845    
Other
         15,153           14,497    
        $ 58,157         $ 71,144    
 
In July 2018, we accelerated the closing date and completed the purchase of intellectual property and certain other assets comprising the MJ Biologics, Inc. (“MJB”) business relating to animal vaccines. The Company and MJB had originally agreed to the purchase business combination in January 2015, with a contemplated final closing date in January 2021. The final amount due, net of previously paid amounts, was $12,775, including $9,000 paid in July 2018 and $3,775 paid in January 2019.
As of
    
December 31,
2018
    
June 30,
2018
  
Accumulated other comprehensive income (loss)                          
Derivative instruments
       $ 3,284         $ 4,986    
Foreign currency translation adjustment
         (70,617)           (67,098)    
Unrecognized net pension gains (losses)
         (17,981)           (18,213)    
(Provision) benefit for income taxes on derivative instruments
         (818)           (1,241)    
(Provision) benefit for income taxes on long-term intercompany investments
         8,166           8,166    
(Provision) benefit for income taxes on pension gains (losses)
         (3,141)           (3,083)    
        $ (81,107)         $ (76,483)